Optimer’s Dificid Gets Medicare Payment “Add-On” For Hospital Patients
This article was originally published in The Pink Sheet Daily
Executive Summary
In a rare application of its Medicare “new technology add-on payments” policy to drugs, the Centers for Medicare and Medicaid Services announced it will supplement reimbursement to hospitals for the oral antibiotic Deficid and methotrexate toxicity antidote Voraxaze.